Research Analysts Set Expectations for DAWN Q3 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Stock analysts at Capital One Financial boosted their Q3 2024 earnings estimates for shares of Day One Biopharmaceuticals in a report released on Wednesday, October 16th. Capital One Financial analyst N. Quibria now forecasts that the company will post earnings of ($0.71) per share for the quarter, up from their previous forecast of ($0.79). The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($1.68) per share. Capital One Financial also issued estimates for Day One Biopharmaceuticals' Q4 2024 earnings at ($0.73) EPS and FY2024 earnings at ($2.21) EPS.

A number of other research firms have also recently issued reports on DAWN. Bank of America upgraded shares of Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and raised their target price for the stock from $11.00 to $24.00 in a research note on Thursday, August 1st. Wedbush restated an "outperform" rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. Needham & Company LLC increased their target price on Day One Biopharmaceuticals from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, October 9th. Piper Sandler reissued an "overweight" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a report on Monday, July 8th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, August 1st. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $35.71.

Day One Biopharmaceuticals Price Performance

Day One Biopharmaceuticals stock traded down $0.08 during mid-day trading on Monday, hitting $14.93. 541,855 shares of the company's stock traded hands, compared to its average volume of 920,466. The firm has a 50 day simple moving average of $14.08 and a two-hundred day simple moving average of $14.37. Day One Biopharmaceuticals has a fifty-two week low of $9.76 and a fifty-two week high of $18.07. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -5.95 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings data on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.70. The business had revenue of $8.19 million during the quarter, compared to the consensus estimate of $0.90 million.

Insider Buying and Selling

In related news, General Counsel Adam Dubow sold 3,202 shares of the firm's stock in a transaction on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $44,828.00. Following the transaction, the general counsel now owns 26,928 shares in the company, valued at approximately $376,992. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the firm's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total value of $426,600.00. Following the sale, the insider now owns 1,097,535 shares of the company's stock, valued at approximately $15,606,947.70. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Adam Dubow sold 3,202 shares of Day One Biopharmaceuticals stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $44,828.00. Following the completion of the transaction, the general counsel now owns 26,928 shares in the company, valued at approximately $376,992. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 48,748 shares of company stock valued at $689,072 over the last 90 days. 8.40% of the stock is owned by corporate insiders.

Institutional Trading of Day One Biopharmaceuticals

Large investors have recently bought and sold shares of the business. Essex Investment Management Co. LLC acquired a new position in Day One Biopharmaceuticals during the third quarter worth about $2,566,000. Handelsbanken Fonder AB lifted its stake in Day One Biopharmaceuticals by 16.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company's stock valued at $376,000 after purchasing an additional 3,900 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in Day One Biopharmaceuticals in the second quarter valued at approximately $124,000. Point72 Asset Management L.P. bought a new stake in shares of Day One Biopharmaceuticals during the second quarter worth $6,480,000. Finally, Deerfield Management Company L.P. Series C grew its stake in shares of Day One Biopharmaceuticals by 65.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 2,923,137 shares of the company's stock worth $40,281,000 after buying an additional 1,157,825 shares during the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.